Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...

On this week's episode of "The Readout LOUD": a closer look at the NIH’s grant-cutting legal playbook, FDA transparency ...

The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment ...

Next month will be the first opportunity to gauge the commercial launch of a new treatment for Prader-Willi syndrome, a rare ...

Cogent Biosciences said its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic ...

The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: MoonLake ...

Feuerstein, 48, grew up on Long Island, N.Y., and majored in political science at Emory University. He got his start in professional journalism while still in college, doing a six-month internship ...

Adam Feuerstein: Powers claims the company's cancer immunotherapy DCVax [ sic, DCVax-L] demonstrated a large and statistically significant survival benefit in a couple of phase I brain tumor ...

Adam Feuerstein's video message of why Antigenics (NASDAQ:AGEN) stinks is another fine example of why the small investor should not trust the big boys to ...